IXICO PLC (LON:IXI)

IXICO PLC (LON:IXI)


Share Price
26.00 p
Change
-0.5 (-1.89 %)
Market Cap
£12.16 m
Proactive Investors - Run By Investors For Investors

IXICO PLC RNS Release

Directorate Change


RNS Number : 0368K
IXICO plc
11 December 2018
 

11 December 2018

 

IXICO plc

 

("IXICO" or the "Company")

 

Directorate change

 

IXICO plc (AIM: IXI), the data science company delivering insights in neuroscience, today announces that Susan Lowther has resigned from her position as Chief Financial Officer and Company Secretary and stepped down from the Board with effect from 11 December 2018. She will leave the Company today to pursue other business interests. Until a successor is appointed, Conor Wolfson, who has been with the Company for over four years as the Group's Financial Controller, will assume the duties of interim Head of Finance.

 

Charles Spicer, Non-Executive Chairman of IXICO, said: "On behalf of the Board, I would like to thank Susan for her many contributions to the Company.  She leaves IXICO in a strong financial position to continue executing on its commercially-led growth strategy. We wish her well in her future endeavours. The search for a replacement Chief Financial Officer has been initiated."

 

For further information please contact:

 

IXICO plc

Giulio Cerroni, Chief Executive Officer

 

Tel: +44 20 3763 7499



Shore Capital (Nomad and Broker)

Edward Mansfield/Anita Ghanekar/Daniel Bush

 

Tel: +44 20 7408 4090



FTI Consulting Limited (Investor Relations)

Simon Conway/Mo Noonan

 

Tel: +44 20 3727 1000

 

About IXICO

 

IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our biopharmaceutical clients' neurological therapeutic pipelines through the application of novel medical imaging and mobile health digital technologies.

 

IXICO's data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.

 

More information is available on www.IXICO.com


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
BOAGMMMZLGKGRZM

IXICO PLC Timeline

Newswire
December 11 2018

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use